UMN: Bio-Med Library - Public Health

THE OVARIAN CANCER RESEARCH FUND, INC.

The Liz Tilberis Scholars Program

Application Deadline: September 15, 2005



This announcement is directed towards junior faculty with a strong commitment
to an investigative career in the field of ovarian cancer research. The
intent of these awards is to support a substantial time commitment to
research and academic endeavors in ovarian cancer.



Liz Tilberis scholarships will be awarded to three individuals working
in institutions with strong existing ovarian cancer research programs.
Proposals should have enough depth to allow the Liz Tilberis Scholar to
compete for additional funding in the future. Candidates must have an
M.D. or Ph.D degree and should be in their first academic appointment
after having completed their fellowship or post-doctoral training. Each
of the three Liz Tilberis Scholars will receive a three-year grant of
$100,000 per annum. Individuals already in a faculty position and those
who will begin such a position by July 2006 are eligible for this award.
Funding is for direct costs only. The investigators and the institution
must certify that at least 75% of the scholar’s time will be dedicated
to ovarian cancer research. Recipients of the awards will be required
to submit annual progress reports to update the status of their research
throughout the award cycle.  For more information visit the Ovarian
Cancer Research Fund website at www.ocrf.org.
Applications are available from Roxy McCann at doni0007@umn.edu

THE OVARIAN CANCER RESEARCH FUND, INC.

The Ovarian Cancer Research Training Programs of Excellence

Application Deadline: September 15, 2005



The Ovarian Cancer Research Training Programs of Excellence award provides
funding for trainees who are working under the supervision of a mentor
who is a recognized leader in the field of ovarian cancer research. Trainees
may be involved in either laboratory, clinical or epidemiology research.
Eligible applicants are clinical fellows or post-doctoral fellows. Awards
will be made to approximately four to five individuals working in institutions
with well-developed ovarian cancer research programs. In addition to the
strength of the research environment and project proposal, selection criteria
include the trainee’s prior academic track record and the likelihood
of them pursuing a research career. Although the trainee may take part
in some non-research activities (e.g. class work, clinical) at least 90%
effort should be devoted to research during the tenure of the OCRF award.

The OCRF research training programs of excellence award provides $75,000.
For more information visit the Ovarian Cancer Research Fund website at
www.ocrf.org. Applications are available
from Roxy McCann at doni0007@umn.edu

AMERICAN CANCER SOCIETY REQUEST FOR APPLICATIONS

Pathogenesis and Treatment of Lymphedema Secondary to the Management of
Breast Cancer

RFA-02-2005,

Letter of Intent due August 15th, 2005

Applications due October 15th, 2005



The American Cancer Society, supported by the Longaberger® Company
is announcing this RFA to investigate the incidence, etiology and new
treatments for secondary lymphedema in human subjects. The purpose of
this RFA is to stimulate research on the modification of morbidity from
lymphedema secondary to treatment for breast cancer and to gain some understanding
of the natural history and effective interventions aimed at minimizing
that morbidity. The scope of this research includes attempts to improve
early diagnosis of affected individuals, the choice and timing of treatment,
the pathophysiology of the disorders of skin and subcutaneous tissue secondary
to chronic lymphedema resulting from breast cancer treatment.



This RFA will use the American Cancer Society targeted Research Scholar
Grant (RSG) award mechanism. The applicant will be solely responsible
for the planning, direction, and execution of the proposed project, which
is not to exceed $150,000 direct plus indirect costs per year a period
of 3 years. It is anticipated that a total of $1,500,000 will be available
for 4 3-4applications selected through the Society’s peer review
system.

http://www.cancer.umn.edu/page/docs/Lymphedema-RFA-FINAL-June05.pdf

CANARY FUND AND THE AMERICAN CANCER SOCIETY POSTDOCTORAL
PROGRAM IN THE EARLY DETECTION OF CANCER

Letter Of Intent: N/A

Application Due Date: October 15, 2005



Canary Fund in partnership with the American Cancer Society has created
a postdoctoral fellowship program focused on studies in the tools and
technologies for developing strategies for the early detection of cancer.
Research should be directed at new approaches to improve clinical methods
for the screening of primary tumors and/or metastases including, but not
limited to research focused in the following areas:

• Minimally invasive strategies for early detection

• Biomarker identification or discovery

• Imaging, including novel molecular imaging strategies



Awards will be 3 years in duration with progressive stipends of $40,000,
$42,000, and $44,000 per year, plus $4,000 per year for institutional
allowance. Based upon the availability of funds and the scientific merit
of the applications, it is anticipated that up to 2 awards will be made.
To restrict funding to full 3 year fellowships, applications will only
be accepted from scientists who, at the time of application, have had
no more than 2 years of research experience beyond their terminal degree
(MD or PhD). Applicants must be US citizens or permanent residents working
with an accomplished mentor at a non-profit institution.

http://www.cancer.umn.edu/page/docs/Canary-F05-RFA-final.pdf



NOTICE OF EXTENSION: PAR-03-148 - CANCER EDUCATION
AND CAREER DEVELOPMENT PROGRAM

NOT-CA-05-024

Release Date: July 29, 2005

The purpose of this Notice is to inform potential applicants that the
expiration date for program announcement PAR-03-148, “ Cancer Education
and Career Development Program” (http://grants.nih.gov/grants/guide/pa-files/PAR-03-148.html),
has been extended. The new expiration date is July 5, 2006.

http://grants.nih.gov/grants/guide/notice-files/NOT-CA-05-024.html



ESTABLISHED INVESTIGATOR AWARD IN CANCER PREVENTION
& CONTROL

PAR-05-145

This is a reissuance of PAR-03-149, which was previously released July
8, 2003.

Letters of Intent Receipt Date(s): Not applicable

Application Submission Dates: February1, June 1, October 1



The NCI Established Investigator Award (K05) provides qualified cancer
research scientists in the fields of cancer prevention, control, behavioral,
and/or population sciences with protected time to devote to research and
to mentoring of new investigators. Candidates must justify their request
for K05 support in terms of need for protected time to devote to research
and mentoring. Candidates must have track records of successful independent
research funding and mentoring. At the time of the K05 award, candidates
must have independent R01 research funding or its equivalent in a research
area related to cancer prevention and control. Candidates for the K05
award may not concurrently apply for or have pending another NIH career
development award. Up to two revisions of a K05 application will be accepted.

The award provides the recipient with annual salary support (up to the
current Federal salary limit) for 25 percent to 50 percent effort, plus
fringe benefits. The award also provides $25,000 per year in research-related
expenses. It is expected that most applicants for the K05 award will request
5 years of funding; requests for K05 support must be for at least 3 years.
The K05 award is renewable one time and for up to an additional 5-year
period. The total amount of funds and the number of K05 grants awarded
will depend upon the quality of applications as determined by the peer
review process, their costs, and available funds.

http://grants.nih.gov/grants/guide/pa-files/PAR-05-145.html



More Information at: http://www.cancer.umn.edu/page/ccmembers/members.html

Posted by Chad Fennell at 05:39 PM | Permalink | TrackBacks (0)

Sponsor: Jose Carreras International Leukemia Foundation (FJCILF)
Deadline: October 15, 2005
Internal coordination required. Only one application will be considered from each institution.

The José Carreras International Leukemia Foundation was founded in 1988 by the internationally known tenor Jose Carreras. The goals of the foundation are to support research into the diagnosis, prevention, and cure of leukemia and related hematological malignancies. Candidates must hold an M.D. or Ph.D. degree and have completed at least three years of postdoctoral training but must be less than ten years from their first doctoral degree when the award begins. Candidates must be able to devote at least 80 percent of their time to the project and must have a sponsoring institution with the academic environment to provide adequate support for the proposed project. Initially, applications will be accepted for one fellowship to provide funding of US $50,000 for one year, renewable yearly for two additional years with satisfactory performance. Indirect costs are not to exceed 8 percent and salary is not to exceed US $35,000 including fringe benefits, with the remainder for supplies and equipment.
http://fundingopps.cos.com/cgi-bin/getRec?id=80897

Posted On: http://www.cancer.umn.edu/page/ccmembers/members.html

Posted by Chad Fennell at 06:12 PM | Permalink | TrackBacks (0)

Please call Kamala Upadhyaya at 626-5326 for assistance with your application.

UNIVERSITY OF MINNESOTA TRANSDISCIPLINARY TOBACCO USE RESEARCH CENTER (TTURC) PILOT GRANT PROGRAM
Applications Due: April 15, 2005

The purpose of the TTURC Pilot Grants Program is to provide seed money to support innovative studies aimed at reducing the harm from tobacco dependence, or strategies to reduce tobacco use among populations that have been refractory to smoking cessation efforts. Proposals may involve any level of inquiry (e.g. molecular, genetic, preclinical, clinical, epidemiologic or public policy). Up to $25,000 for 1 year is available to support pilot projects. This funding may be used for direct costs only.

Potential applicants must first contact the Pilot Projects Program Director (contact information below) to determine whether the proposed project is within the scope of the Center; applications that have not been discussed will not be accepted. Before submitting an application, please contact Roxy McCann at 612-625-2662 or by email at donni0007@umn.edu for submission guidelines. A pdf file with a copy of this announcement is available.

Paul Pentel, M.D.
Pilot Projects Program director
University of Minnesota TTURC
pentel@umn.edu

Link: http://www.cancer.umn.edu/page/ccmembers/members.html

Posted by Chad Fennell at 11:19 AM | Permalink | TrackBacks (0)

Please call Kamala Upadhyaya at 626-5326 for assistance with your application.

THE CONSORTIUM ON LAW AND VALUES IN HEALTH, ENVIRONMENT & THE LIFE SCIENCES

The Consortium on Law and Values in Health, Environment & the Life Sciences (http://www.lifesci.consortium.umn.edu) is pleased to announce 3 funding opportunities for faculty; graduate and professional students; and departments, programs, or centers. This funding initiative aims to encourage work on the broad societal implications of problems in health, environment, or the life sciences.

1. Request for Proposals (RFP) from GRADUATE/PROFESSIONAL STUDENTS to Provide Support for Summer 2005 or 2005-06 (deadline 3/4/05);

2. Request for Proposals (RFP) to Support DEPARTMENT, PROGRAM, or CENTER Colloquia in Summer 2005 or 2005-06 (deadline 4/8/05); and

3. Request for Proposals (RFP) from FACULTY to Fund Interdisciplinary Research, Projects, or Curricular Innovation on Health, Environment, or the Life Sciences in Summer 2005 or 2005-06 (deadline 3/25/05).

The Consortium currently links 17 University programs and centers to examine the legal, ethical, and policy questions raised by the life sciences. The Requests for Proposals (RFPs) deadlines may be found at
http://www.lifesci.consortium.umn.edu/rfps/

If you have questions concerning these RFPs, please contact Ann Hagen at hagen055@umn.edu or 612-625-3356.

Full Article: http://www.cancer.umn.edu/page/ccmembers/members.html

Posted by Chad Fennell at 11:37 AM | Permalink | TrackBacks (0)

unding is now available to support 4 fellowship positions for minority doctoral students. The selected fellows will conduct research related to the efforts of, and within, CDC-funded Prevention Research Centers. Fellowship positions are for a two-year period. The Association of Schools of Public Health (ASPH) will be responsible for coordinating these fellowships.

Full Article: http://www.cancer.umn.edu/page/ccmembers/members.html

Posted by Chad Fennell at 12:35 PM | Permalink | TrackBacks (0)

Please call Kamala Upadhyaya at 626-5326 for assistance with your application.

AMERICAN CANCER SOCIETY, MIDWEST DIVISION 2005 YOUGH SCHOLARSHIP PROGRAM
Application Receipt Date: April 1, 2005

The American Cancer Society (http://www.cancer.org) is proud to
announce the availability of a limited number of college/continuing
education scholarships for students under the age of 21. They must be a
legal resident of Iowa, Minnesota, South Dakota, or Wisconsin for at
least one year and have plans to attend a 2 or 4-year program in the
Fall of 2005. Awards will be $1,000 per individual. This program is
being offered to young people who are cancer survivors.

Please feel free to contact Roxanne Honeyman at 1-800-947-0487 ext. 5536 with any questions or for additional information.

COMMUNITY PROGRAM GRANT RFP ANNOUNCEMENT
Lance Armstrong Foundation (LAF)
Letters of Intent Receipt Date: February 15, 2005, 12:01 a.m. CST

The Lance Armstrong Foundation (LAF) will soon begin accepting applications for funding in Spring 2005 through the Community Program. The LAF is pleased to offer financial support and practical advice to community non-profit organizations serving the needs of cancer survivors as identified by the National Action Plan for Cancer Survivorship. The Foundation seeks to help develop innovative projects that encourage survivors to live strong through the physical, emotional and practical challenges of their survivorship.

The LAF will offer two types of grants in Spring 2005 in support of cancer survivorship initiatives that impact people in their communities. A request for proposals (RFP) and additional guidelines and procedures are now available on our website (www.laf.org) in the Public Health section. The online application system will open on January 3, 2005, and will be accessible through a link on the LAF website. The deadline for Letter of Intent submissions – accepted only through the online system – is 12:01 a.m. CST on February 15, 2005.

To view all grants available through the Cancer Center, visit http://www.cancer.umn.edu/page/aboutus/grantopp.html

Posted by Chad Fennell at 08:57 AM | Permalink | TrackBacks (0)

LETTER OF INTENT RECEIPT DATE: FEBRUARY 15, 2005
APPLICATION RECEIPT DATE: MARCH 1, 2005

We are at the beginning of a major breakthrough in cancer control. The
explosion in knowledge of gene sequence and function, fueled in large part
by the Human Genome Project is already transforming how patients and
physicians evaluate risk, prevention, detection, and the treatment of
cancer. Emerging technologies are enabling rapid, cost-effective, and
coordinate evaluation of an individual’s DNA sequence and complex patterns
of RNA and protein expression. This in turn, presents us with the
challenges of translating such knowledge into clinical management.

Canary Fund in partnership with the American Cancer Society has created a
postdoctoral fellowship program focused on studies in the tools and
technologies for developing strategies for the early detection of cancer.
Research should be directed at new approaches to improve clinical methods
for the screening of cancer including, but not limited to, research focused
in the following areas:
• Minimally invasive strategies for early detection
• Biomarker identification or discovery, particularly protein
biomarkers
• Imaging, including novel molecular imaging strategies

Awards will be 3 years in duration with progressive stipends of $40,000,
$42,000, and $44,000 per year, plus $4,000 per year for institutional
allowance. Based upon the availability of funds and the scientific merit
of the applications, it is anticipated that up to 5 awards will be
made. To reserve funding for full 3 year fellowships, applications will
only be accepted from scientists who at the time of application have had no
more than 2 years of research experience beyond their terminal degree (MD
or PhD). Applicants must be US citizens or permanent residents working
with an accomplished mentor at a non-profit institution. Postdoctoral
fellowships are designed to support a program of research training and
study to enable new investigators to develop the critical skills necessary
for an independent career in cancer research.

The deadline for receipt of applications is March 1, 2005. A letter of
intent is required and should be submitted by February 15th. It should
provide the title of the project, a brief summary of the specific aims, and
an outline (2-3 sentences) of the techniques to be used to achieve the
aims. Awardees will be asked to attend the May 24-26, 2005 Early Detection
Symposium in Palo Alto, California. For additional information regarding
program policies or to obtain an application, please refer to the ACS
website: www.cancer.org/research

For specific inquiries, please contact:

Christopher Widnell, PhD
American Cancer Society, Inc.
404-329-7552
christopher.widnell dnell@cancer.org>@cancer.org

or

William Phelps, PhD
American Cancer Society, Inc.
404-329-6835
william.phelps@cancer. ancer.org>org

Posted by Cindy Gruwell at 06:00 PM | Permalink | TrackBacks (0)

AHC Translational Research Grant Program

The maximal value of scientific discoveries in the health sciences is achieved when new knowledge can be utilized to improve health by preventing or reversing disease. To enhance the translation of research from the bench to the bedside, the Academic Health Center has developed a new grant program, the AHC Translational Research Grant Program. We anticipate funding at least three such grants in 2005. The overall goal is a program that would move concepts developed at this institution from basic work to clinical testing. Successful grantees would need to demonstrate an effective transfer of expertise in the direction of bench-to-bedside. However, not all steps in translation would necessarily be performed within this grant program. The underlying premise is that subsequent to this “seed” funding, any further development of the research would be funded either by the NIH; foundations; or venture capital, existing pharmaceutical or biotechnology companies.

Translational Research Grants are available to faculty members in the AHC with an N, P, I, J, or K appointment and employment through the University. The primary criteria for funding will be innovation, the quality of the research approach, the potential for future outside funding to sustain or further develop the program, and the likelihood of eventual development of a useful product. Awards will be in the amount of $200,000 or less (over two to three years). Awards will be for new projects without outside funding (projects with existing, partial funding will receive the lowest priority). Preference will be given to proposals that create a new collaboration (ie, a new pairing of co-investigators). http://www.ahc.umn.edu/research/funding/translational.

Innovative Technologies for Molecular Analysis of Cancer (SBIR/STTR)

This is a reissue of RFA-CA-05-006
Letters of Intent Receipt Dates: January 17, 2005; May 17, 2005; September 18, 2005
Application Receipt Dates: February 17, 2005; June 17, 2005; October 18, 2005

The National Cancer Institute (NCI) invites applications for research projects proposing the development of highly innovative cancer-relevant technologies. Technology encompasses methods and tools that enable research, including, but not limited to, instrumentation, techniques, and devices. Technology is distinct from resources such as databases, reagents, and tissue repositories. Applications for support of such resources will not be considered responsive to this RFA. Applications may be submitted for support as Phase I STTR (R41) or Phase I SBIR grants (R43), or Phase II STTR (2-R42) or Phase II SBIR (2-R44) grants. Applicants may not simultaneously submit identical/essentially identical applications under both this funding opportunity and the SBIR/STTR Omnibus Solicitation. Phase I/ Phase II Fast-Track applications (1-R42, 1-R44) will not be accepted. The National Cancer Institute intends to commit approximately $1,000,000 dollars in FY 2006 to fund three to five Phase I and/or Phase II applications under the SBIR/STTR set-aside funding mechanism. An applicant may submit an unlimited number of unique applications in response to this announcement, http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-06-005.html


Application of Emerging Technologies for Cancer Research (SBIR/STTR)

This is a reissue of RFA-CA-05-007
Letters of Intent Receipt Dates: January 17, 2005; May 17, 2005; September 18, 2005
Application Receipt Dates: February 17, 2005; June 17, 2005; October 18, 2005

The National Cancer Institute (NCI) invites applications for research projects to evaluate the usefulness of emerging technologies that are ready for initial application to clinical or biological questions in cancer research. Projects should be designed to demonstrate that the technology is robust and yields reproducible measurements. Projects should also be designed to gather preliminary data to support the use of the technology in a future project(s) with a clinical or biological focus. It is expected that some refinement or adaptation of the technology may be appropriate in the initial phase of the project, but projects requiring significant technology development effort are not appropriate. In addition, applications that propose the use of commercially available technology under standard conditions, or any technology that is already commonly accepted for the proposed use, are not appropriate. Applications may be submitted for support as Phase I STTR (R41) or Phase I SBIR grants (R43), or Phase II STTR (2-R42) or Phase II SBIR (2-R44) grants, or the SBIR/STTR Fast-Track option (1-R42 or 1R44) as described in the SBIR/STTR Omnibus Solicitation. The National Cancer Institute intends to commit approximately $1,250,000 dollars in FY 2006 to fund two to four Phase I, Phase II, and/or Fast-Track applications under the SBIR/STTR set-aside funding mechanism. An applicant may submit an unlimited number of unique applications in response to this announcement. http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-06-006.html

Innovations in Cancer Sample Preparation (SBIR/STTR)
This is a reissue of RFA-CA-05-008
Letters of Intent Receipt Dates: January 17, 2005; May 17, 2005; September 18, 2005
Application Receipt Dates: February 17, 2005; June 17, 2005; October 18, 2005

The National Cancer Institute (NCI) invites applications for research projects involving the development and significant enhancement or adaptation of sample preparation methodologies and technologies, the development of assays to assess sample quality, and studies designed to elucidate the criteria by which to judge sample quality. The outcome will be products and methods designed to optimize sample utility. Samples may originate from residual material not necessary for patient care or from cell lines, model organisms, or other sources relevant to cancer research. Applications may be submitted for support as Phase I STTR (R41) or Phase I SBIR grants (R43), or Phase II STTR (2-R42) or Phase II SBIR (2-R44) grants, or the SBIR/STTR Fast-Track option (1-R42 or 1R44) as described in the SBIR/STTR Omnibus Solicitation. The National Cancer Institute intends to commit approximately $1,250,000 dollars in FY 2006 to fund eight to twelve Phase I, Phase II, and/or Fast-Track applications under the SBIR/STTR set-aside funding mechanism. An applicant may submit an unlimited number of unique applications in response to this announcement.
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-06-007.html

Social and Cultural Dimensions of Health

This is a reissue of PA-02-043
Application Receipt Dates: February1, 2005; June 1, 2005; October 1,2005

The ultimate goal of this program announcement is to encourage the development of health research that integrates knowledge from the biomedical and social sciences. This involves the further development of health-related social science research relevant to the missions of the NIH Institutes and Centers (ICs) and the development of multi- or inter-disciplinary research that blends the theories and approaches of the social and biomedical sciences. Within the broad spectrum of research identified in this announcement, applicants are encouraged (but are not required) to employ multiple (i.e., biological, behavioral, and/or social) levels of analysis. This funding opportunity will use the NIH Research (R01) award mechanism. As an applicant, you will be solely responsible for planning, directing, and executing the proposed project. Applications received in response to this program announcement will compete for funds in the general funding pool of the participating NIH ICs. No specific funds have been set aside for this announcement. The number and size of the awards will depend on the number of applications received, their relative scientific merit, and the general availability of funds for investigator-initiated research at the participating ICs. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. http://grants.nih.gov/grants/guide/pa-files/PA-05-029.html

Posted by Cindy Gruwell at 01:01 PM | Permalink | TrackBacks (0)

Innovative/Translational Caner Research - Mary Kay Ash Charitable Foundation
Application Receipt Date: February 15, 2005

Mary Kay Ash Charitable Foundation, a funding source for cancer research, is currently accepting applications for innovative grants for translational research in ovarian, uterine, breast, or cervical cancer. Only one grant application will be accepted from each accredited school. The grant will be up to $100,000 (combined direct and indirect costs) for a two-year period. If indirect costs are requested, they cannot exceed 15%. If selected, the funds will be paid in two payments. Complete application may be requested from Roxy McCann
doni0007@umn.edu or 5-2662.

Translational Research Program 2005 - Leukemia – Lymphoma – Myeloma
Application Receipt Date: March 15, 2005

The Leukemia & Lymphoma Society provides early-stage support for clinical research on leukemia, lymphoma and myeloma, which is intended to develop innovative approaches to treatment, diagnosis or prevention. The program fosters collaboration between basic research findings to clinical usefulness. The Translational Research Program is specifically intended for the support of work that has clinical application as a near-term goal. Proposal should be based on epidemiological, molecular, cellular or integrated systems findings and be conceptually innovative. The application should have a clear plan for the clinical exploitation of the studies proposed. The feature of the proposal will be an important consideration of the review process. Awards will be limited to a maximum of $200,000, which include direct costs and a maximum overhead of $20,000 or 11.1% of the direct costs per year for three years. Renewal funding for two additional years may be available from the Society.
http://www.LLS.org

Pre-Application Meeting for NCI Alliance for Nanotechnology in Cancer
The Office of Technology and Industrial Relations, Office of the Director, National Cancer Institute, will hold a pre-application meeting for investigators planning to submit applications in response to Request for Applications (RFA) to be released under the NCI Alliance for Nanotechnology in Cancer, including RFA CA-05-024 "Centers of Cancer Nanotechnology Excellence" (U54) (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-024.html) and RFA CA-05-026 "Cancer Nanotechnology Platform Partnerships" (R01) (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-026.html). This meeting will provide prospective applicants with an opportunity in a public meeting to receive answers to their questions about the RFA. Representatives from the following offices will be available to answer questions relevant to applications responding to these RFAs: Office of Technology and Industrial Relations (OTIR), NCI; Division of Cancer Biology, NCI; Grants Administration Branch, NCI; and the Special Review and Resources Branch, NCI. Staff will be available to discuss the intent and requirements of the RFA. The complete text of these RFAs will be available via this website as soon as they are posted on the NIH Guide. Potential applicants to these RFAs are not required to attend the pre-application meeting.
http://grants.nih.gov/grants/guide/notice-files/NOT-CA-05-006.html http://grants.nih.gov/grants/guide/notice-files/NOT-CA-05-006.html

Centers of Cancer Nanotechnology Excellence

Letters-Of-Intent Receipt Date: February 25, 2005
Application Receipt Date: March 25, 2005

The NCI invites applications from investigators interested in participating in an initiative to establish up to five Centers for Cancer Nanotechnology Excellence (CCNEs). The CCNEs will be a national resource that will integrate the basic and clinical sciences with engineering to develop and apply nanotechnology to cancer research to accelerate the application of this science to the clinic. Using the NIH U54 cooperative agreement mechanism, the NCI intends to commit approximately $90.8 M in FY 2005-2009 (approximately $20 M in FY 2005) to fund up to five CCNEs. Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his or her institution to develop an application for support. An individual can be the PI on only one application submitted under this announcement. However, an individual may be listed as a participant in multiple CCNE applications provided that his/her research proposals are discrete. Application materials are available from the NIH Office of Extramural Research (OER); http://grants.nih.gov/grants/oer.htm/
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-025.html

Cancer Nanotechnology Platform Partnerships

Letter of Intent Receipt Date: February 25, 2005
Application Receipt Date: March 25, 2005

The National Cancer Institute (NCI) invites applications for research project grants (RPGs) to support development of nanotechnology platforms for basic, applied, and translational multi-disciplinary research that uses nanotechnology (e.g., nanoscale devices or nanomaterials less than 1000 nm in size, although the assembly, synthesis, and/or fabrication of components at dimensions less than 300 nm should be demonstrated ) in cancer research. Proposed projects will be eligible for consideration if they address one or more of the following thematic/programmatic areas of focus: molecular imaging and early detection, in vivo imaging, reporters of therapeutic efficacy, multifunctional therapeutics, prevention and control of cancer, and research enablers. This funding opportunity will use the R01 award mechanism. The NCI intends to commit approximately 7 million dollars in FY 2005 to fund approximately 10 new grants in response to this RFA. An applicant may request a project period of up to 5 years and a budget for total costs up to 1 million dollars per year. An applicant may submit one application in response to this RFA. Application materials are available from the NIH Office of Extramural Research (OER); http://grants.nih.gov/grants/oer.htm .
http://grants.nih.gov/grants/guide/notice-files/NOT-CA-05-006.html

Community Participation in Research

Letters of Intent Receipt Date (s): April 17, 2005, 2006, 2007
Application Receipt Dates(s): May 17, 2005, 2006, 2007

The ultimate goal of this PAR is to support research on health promotion, disease prevention, and health disparities that is jointly conducted by communities and researchers. This PAR invites NIH research project grant (R01) and exploratory/developmental grant (R21) award mechanisms. The number of applications each applicant may submit is unrestricted. http://grants.nih.gov/grants/guide/pa-files/PAR-05-026.html

To view all grants available through the Cancer Center, visit http://www.cancer.umn.edu/page/aboutus/grantopp.html

Posted by Cindy Gruwell at 12:48 PM | Permalink | TrackBacks (0)

Application Receipt Date(s): February 1, 2005, June 1, 2005, October 1, 2005

The purpose of this initiative is to invite applications for research projects that will enhance understanding of human decision-making processes so that individuals can make more informed and satisfying choices regarding their health. The NCI encourages collaborations between basic judgment and decision-making researchers, and applied cancer control researchers that will elucidate single-event decision-making processes at the level of the individual patient or health care provider that are pertinent to cancer prevention, detection, treatment, survivorship, or end-of-life care. For the purpose of this initiative, a single-event decision is defined as a discrete decision made at a specific point in time. This PA will use the NIH exploratory/developmental (R21) award mechanism and the NIH investigator-initiated research project grants (R01) award mechanism. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.

http://grants.nih.gov/grants/guide/pa-files/PA-05-017.html

To view all grants available through the Cancer Center, visit http://www.cancer.umn.edu/page/aboutus/grantopp.html

Posted by Cindy Gruwell at 10:03 AM | Permalink | TrackBacks (0)

Application Receipt Date(s): February 1, 2005, June 1, 2005, October 1, 2005

The purpose of this initiative is to invite applications for research projects that will expand our knowledge of basic decision-making processes underlying initiation and long-term maintenance of healthy lifestyle behaviors that may reduce one's risk of cancer and other chronic diseases, such as cardiovascular disease, diabetes, and addiction. The NCI, NIDA, and NIAAA encourage collaborations between basic judgment and decision-making researchers, and applied cancer control or addiction researchers that will elucidate the basic cognitive and affective processes involved in decisions that are made repeatedly over time, such as adhering to weight-loss programs or smoking cessation programs. This PA uses the NIH exploratory/developmental (R21) award mechanism and the NIH investigator-initiated research project grants (R01) award mechanism. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.

http://grants.nih.gov/grants/guide/pa-files/PA-05-016.html

Posted by Cindy Gruwell at 09:56 AM | Permalink | TrackBacks (0)

Preliminary Application Die Date: March 1, 2005
Full Application Due Date: March 1, 2005

Proposal should be based on epidemiological, molecular, cellular or
integrated systems findings and be conceptually innovative. The
application should have a clear plan for the clinical exploitation of the
studies proposed. The application must indicate the applicant will apply
for a Translational Research Program grant through the Society’s standard
procedure, which, if awarded, may be used for the A4 program’s matching
requirements. Awards will be limited to a maximum of $200,000, which
include direct cost per year for three years. Budget requests should be
carefully justified and funding for two additional years may be available
from the Society. Requests for renewal of support require a competitive
renewal application and must include an TRB-approved clinical trial as the
centerpiece of the research plan.
Inquiries: Director of Research Administration, The Leukemia & Lymphoma
Society, 1311 Mamaroneck Ave., White Plains, NY 10605, phone 914-821-8859,
e-mailresearchprograms@tlls.org

To view all grants available through the Cancer Center, visit

http://www.cancer.umn.edu/page/aboutus/grantopp.html

Posted by Cindy Gruwell at 02:48 AM | Permalink | TrackBacks (0)

Letters Of Intent Receipt Date(s): January 14, 2005
Application Receipt Dates(s): February 11, 2005

This postdoctoral, institutional National Research Service Award (NRSA)
will support the establishment of innovative programs that provide formal
coursework and research training in a new interdisciplinary field to
individuals holding advanced degrees in a different discipline. These
training programs are required to include a behavioral or social science
discipline. The NIH is especially interested in training programs that
integrate the behavioral and/or social sciences with the more traditional
biomedical sciences. It is anticipated that approximately $800,000 in total
costs will be awarded. Three to five awards are anticipated. This RFA will
use the Ruth L. Kirschstein NRSA institutional research training grant
(T32) mechanism.

http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-05-010.html

Posted by Cindy Gruwell at 02:46 AM | Permalink | TrackBacks (0)

Letters of Intent Receipt Date(s): April 11, 2005
Application Receipt Date(s): May 11, 2005

The objective of this RFA is to establish the Leadership of three to six
HIV/AIDS Clinical Trials Networks to carry out the NIAID research agenda in
the following areas: (1) Vaccine Research and Development; (2)
Translational Research/Drug Development; (3) Optimization of Clinical
Management, Including Co-Morbidities; (4) Microbicides; (5) Prevention of
Mother-to-Child Transmission (MTCT) of HIV; and (6) Prevention of HIV
Infection. NIAID and collaborating ICs anticipate awarding $150 million in
FY2006 to fund the Leadership of approximately three to six HIV/AIDS
Clinical Trials Networks. Networks are expected to vary substantially in
size and scope of activities. For this reason, the amount of first-year
awards is expected to vary; however, the range of awards is anticipated to
be from $10 million to $20 million direct costs for the three Network
Leadership components combined.

This funding opportunity will use the U01 award mechanism(s). As an
applicant, you will be solely responsible for planning, directing, and
executing the proposed project.

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-05-001.html

Posted by Cindy Gruwell at 02:44 AM | Permalink | TrackBacks (0)

Letters Of Intent Receipt Date: January 22, 2005
Application Receipt Dates: February 22, 2005

The National Cancer Institute (NCI) invites cooperative agreement
applications (U54) for the implementation of Comprehensive Minority
Institution/Cancer Center Partnerships between Minority-Serving
Institutions (MSIs) and NCI-designated Cancer Centers (or groups of
Centers). The purpose of this grant is to provide opportunities for
intensive collaborations among MSIs and the Cancer Centers in order to
develop stronger national cancer programs aimed at understanding the
reasons behind the significant cancer disparities and impact on minority
populations.

Since the War on Cancer was initiated in 1971, the disparities in cancer
incidence, morbidity, and mortality in underserved racial and ethnic
minority populations and among the socio-economically disadvantaged have
continued to rise. Clearly, more research is needed that specifically
addresses these and other disparities if they are to be eliminated by 2010
(President's Initiative on Race and Health Disparities). This initiative is
also in line with the priority recommendations for DHHS to lead the Nation
in eliminating cancer health disparities (Making Cancer Health Disparities
History).

This funding opportunity will use the National Institutes of Health (NIH)
cooperative agreement specialized center (U54) award mechanism. As an
applicant, you will be solely responsible for planning, directing, and
executing the proposed project. This RFA is a one-time solicitation. For
more information visit

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-021.html

Posted by Cindy Gruwell at 02:43 AM | Permalink | TrackBacks (0)

Receipt date: February 15, 2005

The Division of Cancer Biology (DCB) of the National Cancer Institute (NCI)
announces its intent to provide funds to supplement existing DCB-supported
research projects in FY05 to support and encourage scientific collaboration
among DCB grantees, as well as with other members of the scientific
community. This initiative, known as the Activities to Promote Research
Collaborations (APRC) program, can support collaborative activities that
bring together ideas and approaches from disparate scientific disciplines,
including those not currently supported by DCB. Examples of collaborative
activities include, but are not limited to, initiating new collaborative
research projects, sharing resources and reagents, developing novel
technologies, and organizing cross-disciplinary meetings/workshops. It is
essential, however, that proposed APRC activities be within the overall
scope of the active parent award and that the collaborative activity is new.

There are four areas of special scientific emphasis for FY05: (1)
structural biology; (2) integrative cancer biology; (3) tumor
microenvironment; and (4) mouse models. However, applications focused on
other cancer biology topics are will be accepted. For more information
visit

http://grant s.nih.gov/grants/guide/notice-files/NOT-CA-05-005.html

Posted by Cindy Gruwell at 02:41 AM | Permalink | TrackBacks (0)

The newly revised “Application for a DHHS Public Health Service Grant” (PHS
398, rev. 9/04) instructions and forms are now available and will be
accepted for submission/receipt dates on or after December 1, 2004. All
applications received on or after May 10, 2005 must use the new
instructions and forms. During the transition period, applications using
the previous version (rev. 5/01) of the PHS 398 will be accepted through
May 9, 2005. However, after this date, applications submitted using
instructions and forms other than the PHS 398 (rev 9/04) will be returned
to the applicant.

This edition of the PHS 398 has been extensively rewritten with a focus on
clarity and special emphasis on simplicity and plain language. For more
information visit

http://grants.nih.gov/grants/guide/notice-files/NOT-OD-05-006.html

Posted by Cindy Gruwell at 02:32 AM | Permalink | TrackBacks (0)

Announcement Type: New

Funding Opportunity Number: CE05-012

Catalog of Federal Domestic Assistance Number: 93.136

Key Dates:

Letter of Intent Deadline: December 6, 2004

Application Deadline: February 2, 2005

Full Listing: CDC

Posted by Cindy Gruwell at 08:48 AM | Permalink | TrackBacks (0)

LETTER OF INTENT RECEIPT DATE: January 18, 2005

APPLICATION RECEIPT DATE: February 15, 2005

The National Institutes of Health (NIH), the National Science Foundation (NSF) and the U.S. Department of Agriculture (USDA) (hereafter "the Government" or "the Participating Agencies") invite applications for the establishment of "International Cooperative Biodiversity Groups" (ICBG) to address the interdependent issues of biodiversity conservation, economic capacity, and human health through discovery and development of therapeutic agents for diseases of importance in developing countries, as well as those important to developed countries. Eligibility for this competition is limited to groups that are currently funded by ICBG R21 planning grant awards issued in 2003. The overall goals of the ICBG Program are drug discovery, biodiversity conservation, and economic development.

This RFA will use the NIH U01 award mechanism (Cooperative Agreement) and will support awards of up to $600,000 per year in direct costs for up to four years to carry out the full spectrum of ICBG research and development activities in this RFA.

For more information go to http://grants2.nih.gov/grants/guide/rfa-files/RFA-TW-04-004.html

To view all grants available through the Cancer Center, visit http://www.cancer.umn.edu/page/aboutus/grantopp.html

Posted by Cindy Gruwell at 01:26 PM | Permalink | TrackBacks (0)

Application Receipt Dates(s): February 1, June 1, October 1

The purposes of this Program Announcement (PA) are: (1) to improve the measurement of racial /ethnic discrimination in health care delivery systems through improved instrumentation, data collection and statistical/analytical techniques; (2) to enhance understanding of the influence of racial/ethnic discrimination in health care delivery and its association with disparities in disease incidence, treatment and outcomes among disadvantaged racial/ethnic minority groups; and (3) to reduce the prevalence of racial/ethnic health disparities through the development of interventions to reduce the influence of racial/ethnic discrimination on health care delivery systems in the United States. This funding opportunity will use the NIH Research Project Grant (R01), the Exploratory/Development (R21) and the Small Grant (R03) award mechanisms.

For more information go to http://grants2.nih.gov/grants/guide/pa-files/PA-05-006.html

Posted by Cindy Gruwell at 01:22 PM | Permalink | TrackBacks (0)

Application Receipt Dates(s): February 1, June 1, October 1

The ultimate goal of this program announcement is to build a body of science in symptom cluster identification and intervention in cancer and in immune disorders (acquired or autoimmune). This announcement invites applications to (a) identify and assess biobehavioral characteristics of symptom clusters; or (b) design and test interventions that lead to clear outcomes. A rationale for the choice of a symptom cluster is needed, not just co-occurrence of two or more symptoms. Studies at any point in the disease trajectory, or during the survivorship period are encouraged. The type of mechanism is the Research (R01) Award or the Exploratory/Developmental Research (R21) Award.

For more information go to http://grants2.nih.gov/grants/guide/pa-files/PA-05-004.html

Posted by Cindy Gruwell at 01:19 PM | Permalink | TrackBacks (0)

The goal of the NIH Roadmap is to accelerate and strengthen biomedical research enterprise. During consultation with the extramural scientific community that led to the development of the NIH Roadmap process, it was frequently mentioned that the criteria used to evaluate research grant applications were not placing appropriate emphasis on some important types of biomedical research.

http://grants.nih.gov/grants/guide/notice-files/NOT-OD-05-002.html

Addendum – Specialized Programs of Research Excellence (SPOREs) in Human Cancer for the Year 2004

This addendum is to clarify for applicants the qualifying cancer sites for Gynecological Cancer SPOREs. The GYN or Gynecological Cancer SPORE solicitation is intended for applications focused predominantly on cancers of the endometrium and/or cervix. Applicants cannot propose projects on ovarian cancer; Ovarian Cancer SPOREs are solicited independent of other GYN cancers. Any questions regarding the eligibility or responsiveness of a GYN Cancer SPORE application should be directed to Dr. Jane Fountain, the program director for the Gynecological Cancer SPOREs.

http://grants.nih.gov/grants/guide/notice-files/NOT-CA-05-001.html

Posted by Cindy Gruwell at 01:13 PM | Permalink | TrackBacks (0)

Notice Number: NOT-OD-05-002

Key Dates
Release Date: October 12, 2004

Issued by
National Institutes of Health (NIH), (http://www.nih.gov/)

Background

The goal of the NIH Roadmap is to accelerate and strengthen biomedical research enterprise. During consultation with the extramural scientific community that led to the development of the NIH Roadmap process, it was frequently mentioned that the criteria used to evaluate research grant applications were not placing appropriate emphasis on some important types of biomedical research (see http://nihroadmap.nih.gov/). The Roadmap Trans-NIH Clinical Research Workforce Committee proposed a modification of the NIH Peer Review Criteria for investigator-initiated research grant applications that would better accommodate interdisciplinary, translational, and clinical projects. The updated review criteria were adopted at the August 5, 2004 meeting of the Directors of the NIH Institutes and Centers. According to the schedule shown below, the updated criteria will replace the review criteria adopted on June 27,1997 (see http://grants.nih.gov/grants/guide/notice-files/not97-010.html).

Implementation

These updated review criteria will be effective for research grant applications received on or after January 10, 2005 that fall into the following categories:

Investigator initiated research grant applications;
Investigator initiated research grant applications submitted in response Program Announcements (PAs) whether published before or after this announcement;
Solicited research grant applications submitted in response to Requests for Applications (RFAs) will continue to use the review criteria described in the RFA.

Additional information at: NIH Link

Posted by Cindy Gruwell at 09:39 AM | Permalink | TrackBacks (0)

Letters Of Intent Receipt Date(s): November 17, 2004
Application Receipt Dates(s): December 17, 2004

The sole intent of this planning grant is to provide support for cancer projects and programs for a limited duration of time to perform feasibility studies and obtain preliminary data that will lead to the submission of specific competitive grant applications traditionally supported by the NCI and others.

The NCI intends to commit approximately 2.5 million dollars total costs in FY 05 to fund up to six (three pairs) 3-year and six (three pairs) 4-year new grants in response to this RFA. This funding opportunity will use the NIH planning grant (P20) award mechanism.

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-020.html

Posted by Cindy Gruwell at 02:52 PM | Permalink | TrackBacks (0)

The National Cancer Institute (NCI) is requesting applications from the current awardees of the Academic Public Private Partnership Program (AP4) planning grants. The AP4 initiative will provide support for the formation of new partnerships or significant expansions of existing partnerships among academia, industry, non-profit institutions, and government entities. The partnerships will conduct novel cancer therapeutic, prevention, diagnostic, and imaging intervention-directed research focused on undNCI will contact the current awardees directly regarding application procedures and format.

http://grants.nih.gov/grants/guide/notice-files/NOT-CA-04-015.html

Posted by Cindy Gruwell at 02:52 PM | Permalink | TrackBacks (0)

UNDERSTANDING AND PROMOTING HEALTH LITERACY (PAR-04-116)
LETTER OF INTENT RECEIPT DATE: September 13, 2004; September 13, 2005; September 13, 2006
APPLICATION RECEIPT DATE: October 13, 2004; October 13, 2005; October 13, 2006

The participating Institutes, Centers and Offices of the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ) invite investigators to submit R01 research grant applications on health literacy. The goal of this Program Announcement is to increase scientific understanding of the nature of health literacy and its relationship to healthy behaviors, illness prevention and treatment, chronic disease management, health disparities, risk assessment of environmental factors, and health outcomes including mental and oral health. Increased scientific knowledge of interventions that can strengthen health literacy and improve the positive health impacts of communications between healthcare and public health professionals (including dentists, healthcare delivery organizations, and public health entities), and consumer or patient audiences that vary in health literacy, is needed. Such knowledge will help enable healthcare and public health systems serve individuals and populations more effectively, and employ strategies that reduce health disparities in the population.

The research must involve either: a) health literacy, or one of its many components, as a key outcome, b) health literacy as a key explanatory variable for some other outcome, c) methodological or technological improvement to strengthen research on health literacy, or d) health literacy-focused preventions and interventions.

This PA will use the NIH R01 award mechanism. As an applicant, you will be solely responsible for planning, directing, and executing the proposed project. This PA uses just-in-time concepts. It also uses the modular budgeting format.

For more information go to http://grants.nih.gov/grants/guide/pa-files/PAR-04-116.html

UNDERSTANDING AND PROMOTING HEALTH LITERACY (PAR-04-117)
LETTER OF INTENT RECEIPT DATE: September 13, 2004; September 13, 2005; September 13, 2006
APPLICATION RECEIPT DATE: October 13, 2004; October 13, 2005; October 13, 2006

The participating Institutes, Centers and Offices of the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ) invite investigators to submit R03 research grant applications on health literacy. The goal of this Program Announcement is to increase scientific understanding of the nature of health literacy and its relationship to healthy behaviors, illness prevention and treatment, chronic disease management, health disparities, risk assessment of environmental factors, and health outcomes including mental and oral health. Increased scientific knowledge of interventions that can strengthen health literacy and improve the positive health impacts of communications between healthcare and public health professionals (including dentists, healthcare delivery organizations, and public health entities), and consumer or patient audiences that vary in health literacy, is needed.

The research must involve either: a) health literacy, or one of its many components, as a key outcome, b) health literacy as a key explanatory variable for some other outcome, c) methodological or technological improvement to strengthen research on health literacy, or d) health literacy-focused preventions and interventions.

This PA will use the NIH R03 award mechanism. Examples of the types of projects that ICs support with the R03 include the following: pilot or feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and the development of new research technology. As an applicant, you will be solely responsible for planning, directing, and executing the proposed project. A project period of up to two years and a budget for direct costs of up to two $25,000 modules or $50,000 per year may be requested.

For more information go to http://grants2.nih.gov/grants/guide/pa-files/PAR-04-117.html.

Posted by Cindy Gruwell at 11:08 AM | Permalink

Clinical Interfaces Award Program

Team Awards at the interface of the clinical and basic sciences. Research supported by this program must:
-foster new and collaborative ways of addressing complex problems of human health and disease;
-be conducted by teams that include key investigators from at least three disciplines as equal partners. One of these key investigators must be a clinical investigator; and
-be unique and only achievable through integration of a cross-disciplinary team of investigators.

Disciplines include: the biological, physical, chemical, social and population sciences, mathematics, computer sciences, and engineering. Proposals in all disease areas will be considered. Up to three full grants of up to $2.25 million will be awarded.

Pre-proposal deadline: November 2, 2004.
Award start date: October 1, 2005

Full details and instructions are available on the Doris Duke Charitable Foundation's web site: http://www.ddcf.org/mrp/ciap

Posted by Cindy Gruwell at 09:43 AM | Permalink

This grant is for instructors and assistant professors who have no independent national funding and are engaged in cancer-related research. Cancer related research includes analysis of developmental biology, gene regulation, or alternation of intracellular or extracellular processes that may lead to an improved understanding or therapy of potential or actual oncogenic events in prokaryotic or eukaryotic cells. Funding is available up to $20,000. Applications are being accepted until October 1, 2004. Applications may be obtained by calling 612-626-1926 or sending email to micek003@tc.umn.edu.

Posted by Cindy Gruwell at 09:40 AM | Permalink

6/17/2004 11:34:00 AM

--------------------------------------------------------------------------------

To: National Desk

Contact: CDC Press Office, 404-639-3286

WASHINGTON, June 17 /U.S. Newswire/ -- HHS Secretary Tommy G. Thompson today announced an additional $849 million in awards to states, territories, and four major metropolitan areas to strengthen the ability of government and public health agencies to respond to bioterror attacks, infectious diseases and natural disasters.

"This funding is a critical component to our national security," Secretary Thompson said. "Our state and local public health system is the first line of defense when it comes to detection, reporting and containing a terrorist attack, an infectious disease outbreak or any other public health emergency."

This funding is in addition to $498 million released earlier this month by HHS' Health Resources Services Agency to strengthen hospitals and improve overall response capability. All totaled since Sept. 11, 2001, HHS has invested more than $3.7 billion in strengthening the nation's public health infrastructure.

Article
News Release

Posted by Cindy Gruwell at 02:48 PM | Permalink

This Program Announcement (PA) redefines the NIOSH Small Grant (R03) mechanism, and it supersedes all previous announcements of this grant program.

The National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC) invites small grant applications for research related to occupational safety and health. NIOSH research programs support priority areas identified in the National Occupational Research Agenda (NORA) and other significant programs related to occupational safety and health. The overall purpose of this grants program is to develop knowledge that can be used in preventing occupational diseases and injuries, and to understand better their underlying pathophysiology. The intent of the R03 award is to support small research projects that can be carried out in a short period of time with limited resources. The characteristics, requirements, preparation and review criteria for the small grant application are described in this document. This award may not be used for thesis, dissertation, or postdoctoral research.

Link: http://www2a.cdc.gov/nora/

Posted by Cindy Gruwell at 09:07 AM | Permalink

Partnership for Clear Health Communication member Pfizer Inc is seeking
proposals for short-term research projects (e.g. 6-12 months) that address whether use of Ask Me 3 is accepted and used by patients and providers, and if it improves provider-patient interactions, health outcomes for patients and office or hospital practice management. There is also a need to determine if acceptance, use and outcomes of Ask Me 3 vary among patients who have different sociodemographic backgrounds, and to determineif optimal implementation and use of Ask Me 3 varies in different practice settings.

Pfizer will provide support for up to three research proposals. Total
costs, including both direct and indirect costs, are limited to $70,000
per award.

Ask Me 3 grant applications are due June 1. The online RFP is available
online at the Pfizer Clear Health Communication Web site,

http://www.clearhealthcommunication.org/partnerships_awards.html

and includes additional details on Ask Me 3 background, scope of research, selection criteria and application procedures.

Posted by Cindy Gruwell at 12:08 PM | Permalink